{"id":"W4401668701","doi":"10.1007/s13555-024-01238-5","title":"Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Bausch Health; Sanofi Genzyme; Incyte; CTI Biopharma; Les Laboratories Pierre Fabre; Celldex Therapeutics; Valeant Pharmaceuticals International; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Medac; AbbVie; Baxalta; Celgene; Biogen; Gilead Sciences; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Psoriatic arthritis; Psoriasis; Adverse effect; Population; Internal medicine; Dermatology; Surgery","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03831578,0.0006747025,0.003679814,0.0028219,0.0003188353,0.00207747,0.000712859,0.0008761327,0.001257699],"category_scores_gemma":[0.04121556,0.0004756638,0.00715662,0.004745968,0.0005707841,0.001251622,0.0009600765,0.0009689526,0.0002173562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008669606,"about_ca_system_score_gemma":0.001671376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004375863,"about_ca_topic_score_gemma":0.001319386,"domain_scores_codex":[0.9710298,0.01227577,0.007545393,0.002642997,0.005982189,0.0005238774],"domain_scores_gemma":[0.9041693,0.05323677,0.03164874,0.004330307,0.005223691,0.001391214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.02461928,0.0004419441,0.470422,0.03525429,0.1690304,0.0004616279,0.0003859507,0.003702412,0.003003823,0.0004749847,0.005023524,0.2871799],"study_design_scores_gemma":[0.006195372,0.00929852,0.8294778,0.006584856,0.1192045,0.002036953,0.0002048072,0.002417039,0.001326162,0.001069066,0.02200487,0.0001800251],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.4388994,0.5368603,0.005367474,0.00149156,0.0001481527,0.001717252,0.0116486,0.0001489034,0.003718276],"genre_scores_gemma":[0.8995275,0.08277234,0.00354047,0.00131964,0.0002597532,0.0009581361,0.01127481,0.00005112123,0.0002961918],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.03831578,"threshold_uncertainty_score":0.2026357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04121194750481737,"score_gpt":0.3684384994092988,"score_spread":0.3272265519044814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}